Larkspur Health (NASDAQ:LSPR) announced this afternoon that it has secured commitments of $10 million for its proposed merger with specialty biopharmaceutical company ZyVersa.
Of that $10 million, $8.5 million will be a PIPE investment in the form of contingent financing that will provide for the purchase of Convertible Preferred Stock of LSPR. Larkspur Health had originally planned to supplement the deal with a $7 million PIPE, which was also contingent upon ZyVersa obtaining additional interim financing, but the SPAC was able to bring in $1.5 million more than expected.
The remaining amount of today’s announced capital is part of a bridge, an interim finance round of approximately $1.5 million. The commitment is from an offering of Series A Convertible Preferred Stock of ZyVersa which will convert into ZyVersa common stock in connection with the transaction.
Capital raised in the bridge will be used to support the advancement of research and development programs and ongoing ZyVersa operations and, along with funds from the PIPE Investment, will be used by the combined company following the business combination for similar purposes.
The PIPE Investment is anticipated to close simultaneously with the closing of the transaction, which is still expected to take place in the fourth quarter of 2022. Upon closing of the deal, Larkspur is expected to be renamed ZyVersa Therapeutics, Inc. and will continue to operate under the ZyVersa management team, led by Stephen C. Glover, Co-Founder, CEO, and Chairman. The combined company’s common stock is expected to be listed on NASDAQ under ticker symbol “ZVSA.”
The SPAC announced its $108.9 million deal with ZyVersa just a few months ago on July 21, 2022. Weston, Florida-based ZyVersa is developing clinical and preclinical treatments for a variety of inflammatory diseases affecting the kidneys and nervous system.
A look at Plus’ software-first approach to autonomous trucking. After years of investment and excitement, the dawn of self-driving cars and trucks is now here. The question now is which business model among autonomous driving technology companies will win out? This week, we speak with David Liu, CEO of autonomous trucking company Plus. Plus announced...
At the SPAC of Dawn One thing that SPAC investors can typically count on while their money is invested in a SPAC’s trust is that it is going to grow one way or the other between now and their next redemption opportunity, but the devil can occasionally be in the details. In 2024, it became...
Thunderstone has filed for a $50 million SPAC to put a new first-time Asia-based team in action on a generalist hunt. The new SPAC is offering investors a right to a 1/8 share in each unit with 18 months to initially complete a business combination. It is the 8th fresh S-1 filed with underwriter D....
At the SPAC of Dawn In a trading session that may find itself built around the release of Fed minutes at 2 pm ET this afternoon, a pair of SPAC targets have added their own fresh information to the mix. Enterprise AI firm Fusemachines, which has a pending combination with CSLM (OTC:CSLMF), put out a...
Globa Terra Acquisition Corporation (NASDAQ:GTERU) announced the pricing of its $152 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GTERU”, Wednesday, July 9, 2025. The new SPAC plans to mount a search for a target in the agriculture, agtech or biotech sectors with an emphasis on water...